1Wollina U, Koch A, Scheibe A, et al.Targeted 307 nm UVB-pho- totherapy in psoriasis. A pilot study comparing a 307 nm excimer light with topical dithranol[J]. Skin Res Technol, 2012,18(2):212-218.
2Garber K. Anti-IL-17 mAbs herald new options in psoriasis [J]. Nat Biotechnol, 2012,30(6):475-477.
3EI-Saie LT, Rabie AR, Kamel MI, et al. Effect of narrowband ultravio- let B phototherapy on serum folic acid levels in patients with psoriasis [J]. Lasers Med Sci, 2011,26(4):481-485.
4Garber K.Psoriasis: from bed to bench and back [J]. Nat Biotechnol, 2011,29(7):563-566.
5Bremmer S, Van Voorhees AS, Hsu S. Obesity and psoriasis:from the Medical Board of the National Psoriasis Foundation [J].J Am Acad Dermatol, 2010,63(6): 1058-1069.
6Emerit I, Antunes J, Silva JM, et al. Clastogenic plasma factors in pso- riasis--comparison of phototherapy and anti-TNF-o treatments [J]. Photochem Photobiol, 2011,87(6): 1427-1432.
7Sun LD, Cherig H, Wang ZX. Association analyses identify six new psoriasis susceptibility loci in the Chinese population [J]. Nat Genet, 2010,42(11):1005-1009.
8Jung K, Lee D, Lim HS, et al. Double Anti-angiogenic and Anti-in- flammatory Protein Valpha Targeting VEGF-A and TNF- {alpha} in Retinopathy and Psoriasis[J]. J Biol Chem, 2011,286(16):14410-14418.
9Gourraud PA, Le Gall C, Puzenat E, et al. Why statistics matter: Lim- ited inter-rater agreement prevents using the psoriasis area and severity index as a unique determinant of therapeutic decision in psoriasis[J]. J Invest Dermatol, 2012,132(9):2171-2175.
10Shapiro J, Cohen AD, Wcitzman D, ct al. Psoriasis and cardiovascu- lar risk factors: a case-control study on inpatients comparing psoriasis to dermatitis[J]. J Am Acad Dermatol, 2012,66(2):252-258.
